FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/01/062127 [Registered on: 31/01/2024] Trial Registered Prospectively
Last Modified On: 30/01/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A Study Comparing Iberdomide, Daratumumab And Dexamethasone Versus Daratumumab, Bortezomib, And Dexamethasone In Subjects With Relapsed Or Refractory Multiple Myeloma  
Scientific Title of Study   A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab And Dexamethasone (IBERDD) Versus Daratumumab, Bortezomib, And Dexamethasone (DVD) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM) 
Trial Acronym  EXCALIBER-RRMM 
Secondary IDs if Any  
Secondary ID  Identifier 
2020-000431-49  EudraCT 
CC-220-MM-002_Protocol Amendment 3.0 _20Sep2022  Protocol Number 
IND NUMBER: 129254  Other 
NCT04975997  ClinicalTrials.gov 
U1111-1260-2872  UTN 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name   
Designation   
Affiliation   
Address 




 
Phone    
Fax    
Email    
 
Details of Contact Person
Scientific Query
 
Name  Rashmi Chitgupi 
Designation  Country Head - Clinical Management 
Affiliation  PPD Pharmaceutical development Pvt Ltd. 
Address  PPD Pharmaceutical development Pvt Ltd., 101, A Wing, Fulcrum Hiranandani Business Park, Andheri, Mumbai

Mumbai
MAHARASHTRA
400099
India 
Phone  912266022900  
Fax    
Email  rashmi.chitgupi@ppd.com  
 
Details of Contact Person
Public Query
 
Name  Rashmi Chitgupi 
Designation  Country Head - Clinical Management 
Affiliation  PPD Pharmaceutical development Pvt Ltd. 
Address  PPD Pharmaceutical development Pvt Ltd., 101, A Wing, Fulcrum Hiranandani Business Park, Andheri, Mumbai

Mumbai
MAHARASHTRA
400099
India 
Phone  912266022900  
Fax    
Email  rashmi.chitgupi@ppd.com  
 
Source of Monetary or Material Support  
Celgene Corporation 86 Morris Avenue Summit, NJ 07901 
 
Primary Sponsor  
Name  Celgene Corporation  
Address  86 Morris Avenue Summit, NJ 07901 
Type of Sponsor  Pharmaceutical industry-Global 
 
Details of Secondary Sponsor  
Name  Address 
PPD Pharmaceutical Development India Private Limited  101-A Wing Fulcrum, Hiranandani Business Park, Sahar Road, Andheri East, Mumbai – 400 099 
 
Countries of Recruitment     Argentina
Australia
Austria
Belgium
Brazil
Canada
China
Czech Republic
Denmark
Finland
France
Germany
Greece
India
Ireland
Israel
Italy
Japan
Mexico
Netherlands
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Taiwan
Turkey
United Kingdom
United States of America
Republic of Korea  
Sites of Study  
No of Sites = 6  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Neeraj Sidharthan  Amrita Institute of Medical Sciences and Research Centre  Dept. of Clinical Haematology and Stem Cell Transplant Unit, AIMS Ponekkara P O, Kochi – 682041, Kerala, India
Ernakulam
KERALA 
9946047464
4842852020
neerajsidharthan@aims.amrita.edu 
Dr Biswajit Dubashi  Jawaharlal Institute of Postgraduate Medical Education and Research  Department of Medical oncology, 3rd Floor, Dhanvantari Nagar, JIPMER, Puducherry, 605006, India
Perambalur
TAMIL NADU 
8056338405

dr.biswajitdm@gmail.com 
Dr Santhosh Kumar Devadas  M.S. Ramaiah Medical College and Hospital  Room No-10, Ground Floor, M S Ramaiah Nagar, Msrit Post, New Bel Rd Bengalore, Karnataka 560054, India
Bangalore
KARNATAKA 
9036939296

drsanthoshkumar28@gmail.com 
Dr Udip Dilip Maheshwari  Mumbai Oncocare Centre (Unit of Cellcure Cancer Centre Pvt Ltd)  1 to 4, Floor-1st, Shreepati Arcade, August Kranti Marg, Nana Chowk, Mumbai, Maharashtra, India- 400036
Mumbai
MAHARASHTRA 
7677434237

drudipdm@mocindia.co.in 
Dr Rajib De  Nil Ratan Sircar Medical College and Hospital  Department of Haematology, 138, A.J.C Bose Road, Kolkata, West Bengal - 700014
Kolkata
WEST BENGAL 
9433196143

rajibdrde@gmail.com 
Dr Ganesh S Jaishetwar  Yashoda Hospitals  Room no-156, Floor-1st, Department-OPD 5 Hitech City, Cyber Towers to JNTU Road, Hyderabad-500084, India
Hyderabad
TELANGANA 
9849388806

ganeshjaishetwar@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 6  
Name of Committee  Approval Status 
Ethics Committee, M.S. Ramaiah Medical College and Hospital  Approved 
Institutional Ethics Committee, Amrita Institute of Medical Sciences  Submittted/Under Review 
Institutional Ethics Committee, NRSMC  Submittted/Under Review 
Institutional Ethics Committee- Human Studies  Submittted/Under Review 
Mumbai Oncocare Centre Institutional Ethics Committee  Approved 
Yashoda Academy of Medical Education and Research  Submittted/Under Review 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C900||Multiple myeloma,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Treatment Arm A: IBERDOMIDE, DARATUMUMAB AND DEXAMETHASONE (IBERDD)  Oral iberdomide at 1, 1.3 or 1.6 mg once daily from Days 1 to 21 of a 28-day cycle Daratumumab administered as 1800 mg subcutaneously co-formulated with 30,000 units of recombinant human hyaluronidase (rHuPH20) for: - Cycles 1 and 2 on Days 1, 8, 15 and 22 of a 28-day cycle - Cycles 3 to 6 on Days 1 and 15 of a 28-day cycle - Cycles 7+ on Day 1 of a 28-day cycle Oral dexamethasone will be administered at a total dose of 40 mg weekly on Days 1, 8, 15 and 22. For subjects older than 75 years, underweight (body mass index [BMI] 18.5), have poorly controlled diabetes, or prior intolerance/adverse event to steroid therapy, dexamethasone may be administered at a dose of 20 mg weekly on Days 1, 8, 15 and 22. - On daratumumab administration days, dexamethasone will be utilized as the treatment dose of steroid for that particular day, as well as the required premedication prior to the daratumumab administration. Total duration - Treatment will continue until confirmed PD, unacceptable toxicity, or withdrawal of consent 
Comparator Agent  Treatment Arm B: DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (DVD)  Daratumumab administered as 1800 mg subcutaneously co-formulated with 30,000 units recombinant human hyaluronidase (rHuPH20) for: - Cycles 1 to 3 on Days 1, 8 and 15 of a 21-day cycle - Cycles 4 to 8 on Day 1 of a 21-day cycle - Cycles 9+ on Day 1 of a 28-day cycle Bortezomib administered subcutaneously at a starting dose of 1.3 mg/m2 for: - Cycles 1 to 8 on Days 1, 4, 8 and 11 of a 21-day cycle Oral dexamethasone will be administered at a starting dose of 20 mg for: - Cycles 1 to 8 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle. For subjects older than 75 years, underweight (BMI 18.5), have poorly controlled diabetes, or prior intolerance/adverse event to steroid therapy, dexamethasone may be administered at a dose of 10 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12. - On daratumumab administration days, dexamethasone will be utilized as the treatment dose of steroid for that particular day, as well as the required premedication prior to the daratumumab administration. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject is more than or equal to 18 years (there is no upper age limit) of age at the time of signing the informed consent form (ICF)
2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements
4. Subject has documented diagnosis of MM and measurable disease, defined as any of the following:
a. M-protein quantities more than or equal to 1 g/dL by serum protein electrophoresis (sPEP) or more than or equal to 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP); or
b. Light chain MM without measurable disease in serum or urine: serum-free light chain (FLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio
5. Subject has received one to 2 prior lines of anti-myeloma therapy
6. Subject achieved a response (partial response [PR] or better) to at least 1 prior antimyeloma regimen.
7. Subject must have documented disease progression during or after their last anti-myeloma regimen.
8. Prior treatment with CD38-directed therapy:
In Stage 1, subjects with prior CD38-directed therapy are not eligible.
In Stage 2, prior treatment with CD38-directed therapy is permitted only if all the following are fulfilled:
a. Best response achieved during CD38-directed-containing therapy was > PR.
b. Subject did not progress while receiving CD38-directed therapy or within 60 days of last dose of therapy.
c. Subject did not discontinue CD38-directed therapy due to a related AE.
d. Last dose of daratumumab was more than or equal to 3 months prior to randomization.
9. Prior treatment with bortezomib therapy is permitted, if all the following are fulfilled:
a. Best response achieved during bortezomib-containing therapy was at least a minimal response (MR).
b. Subject did not progress while receiving bortezomib therapy or within 60 days of last dose of therapy.
10. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
11. Females of childbearing potential (FCBP) must:
 
 
ExclusionCriteria 
Details  The presence of any of the following will exclude a subject from enrollment:
1. Subject has any significant medical condition, including active or uncontrolled infection, presence of laboratory abnormality, or psychiatric illness that places the subject at an unacceptable risk for treatment-related complications, if he/she were to participate in the study.
2. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 14 days for mild or asymptomatic infections or within 28 days for severe/critical illness prior to randomization.
3. Subject has any condition that confounds the ability to interpret data from the study.
4. Subject has any of the following laboratory abnormalities:
a. Absolute neutrophil count (ANC) < 1,000 cells/µL. It is not permissible to administer granulocyte colony-stimulating factor (GCSF) to achieve minimum ANC levels.
b. Platelet count: < 75,000 cells/µL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count < 50,000 cells/µL for subjects in whom ≥ 50% of bone marrow nucleated cells are plasma cells. It is not permissible to transfuse subjects to achieve minimum platelet counts.
c. Hemoglobin < 8 g/dL (< 4.9 mmol/L).
d. Estimated glomerular filtration rate (eGFR) < 30 mL/min or requiring dialysis. The eGFR should be calculated using the Modification of Diet in Renal Disease (MDRD) formula adjusted for actual BSA
e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L).
f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN).
g. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert’s syndrome.
5. Subject has plasma cell leukemia, Waldenstrom’s macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis.
6. Subject has peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain.
7. Subject has gastrointestinal disease that may significantly alter the absorption of iberdomide and/or other oral study treatment.
8. Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for more than or equal to 5 years with the exception of the following noninvasive malignancies:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin in situ (stage 0)
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative
9. Subject with known central nervous system involvement with MM.
10. Subject has received immunosuppressive medication within the last 14 days of initiating study treatment. The following are exceptions to this criterion:
- Intranasal, inhaled, topical or local corticosteroid injections (eg, intra-articular injection)
- Systemic corticosteroids at doses that do not exceed 10 mg/day of prednisone
- Steroids as premedication for hypersensitivity reactions
11. Subject has impaired cardiac function or clinically significant cardiac disease, including:
a. Myocardial infarction within 1 year before randomization, or an unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure New York Heart Association Class III-IV)
b. Uncontrolled cardiac arrhythmia (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0 Grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities.
12. Subject received prior therapy with iberdomide.
13. Subject received any of the following:
a. Plasmapheresis within the last 28 days of initiating study treatment
b. Major surgery (as defined by the Investigator) within 28 days of initiating study treatment.
c. Radiation therapy, other than local palliative therapy, for myeloma associated bone lesions within 14 days of initiating study treatment.
d. Use of any systemic anti-myeloma drug therapy within 14 days of initiating study treatment
14. Subject received any investigational agent within 28 days.
- Subjects who are participating in other interventional trials may not participate in BMS clinical trials, except for those who have completed treatment with the prior investigational agent(s) and are currently in Long-term Follow up.
- Trial participation for subjects who have received an investigational vaccine (such as an investigational SARS-CoV-2 vaccine) will be determined by discussion between the Investigator and Sponsor Medical Monitor.
15. Subject has previously received a live vaccine within 3 months of initiating study
treatment.
16. Concurrent administration of a strong inhibitor or inducer of cytochrome P450 (CYP3A4/5) (including within 14 days of initiating study treatment).
17. Subject is unable or unwilling to undergo protocol required thromboembolism or herpes zoster prophylaxis.
18. Subject has previously received allogeneic stem cell transplantation at any time during prior therapy or received autologous stem cell transplantation within 12 weeks of initiating study treatment.
19. Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. Note that forced expiratory testing (FEV1) is required for subjects suspected of having COPD.
20. Subject has known moderate or severe persistent asthma within the last 2 years, or currently has uncontrolled asthma of any classification.
21. Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during participation in the study.
22. Subject is positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, active hepatitis A, or active hepatitis C:
a. Known to be seropositive for HIV.
b. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Subjects with resolved infection (ie, subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR.
c. Known to be seropositive for hepatitis C virus (HCV); anti-HCV antibody positive or HCV- ribonucleic acid (RNA) quantitation positive, except in the setting of a sustained virologic response (SVR), defined as aviremia at least 12 weeks after
completion of antiviral therapy.
23. Subject has known allergies, hypersensitivity, or intolerance to boron or mannitol, hyaluronidase, sorbitol, corticosteroids, monoclonal antibodies or human proteins, cereblon modulating agents or their excipients
24. Subject has any contraindications to daratumumab, bortezomib or dexamethasone, per local PI.
25. Vulnerable, under judicial protection, people without freedom by administrative or judicial decision, people with psychiatric conditions without their consent, people accepted in a health or social institution for other purposes than the research, adults under legal guardianship, curatorship, and people incapable of giving consent personally. 
 
Method of Generating Random Sequence   Stratified randomization 
Method of Concealment   Centralized 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Progression-free survival
(PFS) 
Time from randomization to the first documentation of progressive disease according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma 2016 or death due to any cause, whichever occurs first. 
 
Secondary Outcome  
Outcome  TimePoints 
Overall Survival  Time from randomization to death from any cause.
 
Minimal Residual Disease Negativity Rate  Sensitivity of a minimum of 1 in 10 raise to power of 5 nucleated cells by next generation flow cytometry in bone marrow aspirate for subjects who are CR or better per IMWG Uniform Response Criteria for Multiple Myeloma. 
Overall response rate (ORR)  Proportion of subjects who achieve PR or better response according to the IMWG criteria 
Time to response (TTR)   Time from randomization to the first documentation of response (PR or better). 
Duration of response (DoR)  Time from initial documented response (PR or better) until the first date the response criteria are met for PD or death due to any cause, whichever occurs
first. 
Time to progression (TTP)   Time from randomization to the first documented disease progression. 
Time to next treatment (TTNT)   Time from randomization to the start of the subject receiving any anti-myeloma treatment other than study treatment. Subjects who do not start new
anti-myeloma therapy are censored at the last assessment date or follow-up visit known to have
not received new anti-myeloma treatment, whichever is later. 
Progression-free survival 2 (PFS2)   Time from randomization to documented disease progression on next-line therapy, or death from any cause, whichever occurs first. 
 
Target Sample Size   Total Sample Size="664"
Sample Size from India="41" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   09/02/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  14/07/2022 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="5"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Open to Recruitment 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
This is a two-stage, multicenter, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of IberDd versus DVd in subjects with Relapsed or Refractory Multiple Myeloma (RRMM).

India will participate in Stage 2 of the study.

Primary Objective

·       To compare the efficacy of iberdomide, daratumumab and dexamethasone (IberDd) to that of daratumumab, bortezomib and dexamethasone (DVd) in terms of progression-free survival (PFS) in subjects with relapsed or refractory multiple myeloma (RRMM)

 

Secondary Objective(s):

·       To evaluate overall survival (OS) in subjects with RRMM treated with IberDd compared to DVd

·       To evaluate achievement of minimal residual disease (MRD) negative status in subjects with RRMM (who achieve complete response [CR] or better) when treated with IberDd compared to DVd

·       To evaluate additional efficacy parameters in subjects with RRMM treated with IberDd compared to DVd

·       To evaluate safety of IberDd compared to DVd in subjects with RRMM

·       To evaluate cancer-related symptoms and health-related quality of life (HRQoL) using the European Organization for Research and Treatment of Cancer – Quality of Life C30 questionnaire (EORTC QLQ-C30) and the European Quality of Life Multiple Myeloma Module (EORTC QLQMY20) in subjects with RRMM treated with IberDd compared to DVd

 

Stage 2:

In Stage 2 of the study, approximately 664 additional subjects will be randomized 1:1 between 2 treatment arms:

- Approximately 332 subjects will be randomized to receive Treatment Arm A (IberDd)

- Approximately 332 subjects will be randomized to receive Treatment Arm B (DVd)

The total number of subjects enrolled in Stage 2 will be adjusted according to the number of subjects enrolled in the selected iberdomide dose level arm and in the DVd arm during Stage 1.

Overall, approximately 764 subjects are planned to be enrolled in these 2 arms considering Stage 1 and Stage 2 combined.

Length of Study:

The study will consist of the following consecutive periods: Screening, Treatment and Follow-up.

- The Screening period may not exceed a 28-day window prior to randomization (Day -28 to Day -1).

- The Treatment period will extend from randomization to discontinuation of all study treatment.

- The Follow-up period consists of the 28-day Follow-up Visit, the PFS Follow-up Phase, and the Long-term Follow-up Phase.

 


 
Close